Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marathon Petroleum
MPC
|
+$152M |
| 2 |
AT&T
T
|
+$119M |
| 3 |
Norfolk Southern
NSC
|
+$117M |
| 4 |
CSX Corp
CSX
|
+$115M |
| 5 |
Booking.com
BKNG
|
+$104M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$187M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$156M |
| 3 |
C.H. Robinson
CHRW
|
+$134M |
| 4 |
PARA
Paramount Global Class B
PARA
|
+$130M |
| 5 |
BCR
CR Bard Inc.
BCR
|
+$100M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 18.4% |
| 2 | Industrials | 9.75% |
| 3 | Financials | 7.9% |
| 4 | Consumer Staples | 7.89% |
| 5 | Healthcare | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Amdocs
DOX
$6.48B
| $308K | ﹤0.01% |
+5,100
| New | +$286K |
|
|
LMNX
1002
DELISTED
Luminex Corp
LMNX
| $307K | ﹤0.01% |
15,845
-25,120
| -61% | -$478K |
|
1003
Crown Holdings
CCK
$13B
| $306K | ﹤0.01% |
6,172
-617,640
| -99% | -$29M |
|
|
TBI
1004
Trueblue
TBI
$325M
| $306K | ﹤0.01% |
+11,689
| New | +$271K |
|
|
XYZ
1005
Block Inc
XYZ
$48.9B
| $306K | ﹤0.01% |
+20,000
| New | +$217K |
|
|
MNK
1006
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $304K | ﹤0.01% |
+4,956
| New | +$317K |
|
1007
MKS Inc
MKSI
$18.2B
| $303K | ﹤0.01% |
+8,060
| New | +$275K |
|
1008
V2X
VVX
$2.43B
| $303K | ﹤0.01% |
13,300
-3,890
| -23% | -$77.1K |
|
1009
APA Corp
APA
$15.1B
| $301K | ﹤0.01% |
+6,160
| New | +$256K |
|
|
VMRK
1010
Vivmark Residential
VMRK
$25.5B
| $301K | ﹤0.01% |
+4,015
| New | +$300K |
|
1011
Morgan Stanley
MS
$336B
| $298K | ﹤0.01% |
11,900
-276,020
| -96% | -$7.04M |
|
|
BSFT
1012
DELISTED
BroadSoft, Inc.
BSFT
| $296K | ﹤0.01% |
7,330
-150
| -2% | -$5.08K |
|
1013
Manitowoc
MTW
$710M
| $293K | ﹤0.01% |
+16,923
| New | +$246K |
|
|
BBBY
1014
DELISTED
Bed Bath & Beyond Inc
BBBY
| $292K | ﹤0.01% |
5,884
+1,590
| +37% | +$74.5K |
|
1015
DHI Group
DHX
$183M
| $291K | ﹤0.01% |
36,115
+11,380
| +46% | +$93.5K |
|
1016
Grand Canyon Education
LOPE
$3.85B
| $291K | ﹤0.01% |
6,800
-2,500
| -27% | -$96.3K |
|
1017
Welltower
WELL
$173B
| $289K | ﹤0.01% |
+4,167
| New | +$269K |
|
1018
Progress Software
PRGS
$1.78B
| $288K | ﹤0.01% |
11,954
-4,840
| -29% | -$119K |
|
|
CPN
1019
DELISTED
Calpine Corporation
CPN
| $287K | ﹤0.01% |
18,945
-1,411,573
| -99% | -$19.8M |
|
1020
Ethan Allen Interiors
ETD
$592M
| $285K | ﹤0.01% |
+8,960
| New | +$250K |
|
|
DTLK
1021
DELISTED
Datalink Corp
DTLK
| $284K | ﹤0.01% |
31,040
+3,410
| +12% | +$24.6K |
|
|
MTOR
1022
DELISTED
MERITOR, Inc.
MTOR
| $283K | ﹤0.01% |
35,173
+24,190
| +220% | +$176K |
|
|
PIR
1023
DELISTED
Pier 1 Imports, Inc.
PIR
| $283K | ﹤0.01% |
2,021
+63
| +3% | +$6.42K |
|
1024
Intuitive Surgical
ISRG
$132B
| $282K | ﹤0.01% |
4,230
-9,450
| -69% | -$586K |
|
|
QADA
1025
DELISTED
QAD Inc.
QADA
| $282K | ﹤0.01% |
13,280
-6,270
| -32% | -$121K |
|
Similar funds
Dmitry Balyasny's Q1 2016 Portfolio in Review
As of Q1 2016, Dmitry Balyasny held 1,764 positions worth $16.8B, up 17% from $14.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Dmitry Balyasny deployed $2.2B of net new capital in Q1 2016, opening 564 new positions and adding to 341 existing holdings. Its largest new stake was Norfolk Southern: 1,546,641 shares worth $129M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $187M trimmed.
- Dmitry Balyasny's largest Q1 2016 buy was Norfolk Southern: 1,546,641 shares worth $129M.
- Dmitry Balyasny added most to Marathon Petroleum in Q1 2016, an estimated $152M increase.
- Dmitry Balyasny's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $187M.
- Dmitry Balyasny fully exited Union Pacific in Q1 2016, selling an estimated $79.7M.
- Dmitry Balyasny's ten largest holdings make up 12% of its $16.8B portfolio in Q1 2016.
- Dmitry Balyasny opened 564 new positions and closed 526 in Q1 2016.
- Dmitry Balyasny's portfolio value rose 17% quarter-over-quarter to $16.8B.
Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.